Dacliximab
Dacliximab is a monoclonal antibody that is used in the treatment of multiple sclerosis. It is a humanized IgG1 monoclonal antibody that binds to CD25, a receptor subunit that is expressed on the surface of T lymphocytes.
Mechanism of Action[edit | edit source]
Dacliximab works by binding to the alpha subunit (CD25) of the high-affinity interleukin-2 receptor on T cells. This binding inhibits the activation of T cells, which are known to play a role in the pathogenesis of multiple sclerosis.
Clinical Use[edit | edit source]
Dacliximab is used in the treatment of relapsing forms of multiple sclerosis. It is administered as a subcutaneous injection once a month.
Side Effects[edit | edit source]
The most common side effects of dacliximab include rash, lymphadenopathy, and nausea. Serious side effects can include liver damage, immune disorders, and infections.
Contraindications[edit | edit source]
Dacliximab is contraindicated in patients with a known hypersensitivity to dacliximab or any of its components. It is also contraindicated in patients with severe liver impairment.
Drug Interactions[edit | edit source]
Dacliximab may interact with other drugs that affect the immune system, such as corticosteroids and immunosuppressants.
See Also[edit | edit source]
Dacliximab Resources | ||
---|---|---|
|
|
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD